Sept 30 (Reuters) - Trillium Therapeutics Inc TR.TO :
* Completed manufacture of clinical-grade drug product, has proposed a design
for its first-in-human clinical trial with tti-621
* Plans to conduct a phase i trial with a dose-escalation stage that will
enroll patients with relapsed or refractory lymphoma
* Says continues to explore the therapeutic potential of tti-621 in a variety
of solid tumor models
* Source text for Eikon ID:nMKWs21g1a
* Further company coverage TR.TO